Stocks
Immunome (IMNM) EBITDA margin US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -199.7% | -1 674% | -3 042% | -5 829% | ||||
| Changes by years, y/y, % | -1 474pp | -1 368pp | +290.3% | ||||||
Immunome. EBITDA margin, %
Immunome. EBITDA margin, changes, pp
Immunome (IMNM) EBITDA margin US GAAP (quarter values) |
||||||||
| 2024Q2 | 2024Q3 | 2024Q4 | 2025Q1 | 2025Q2 | LTM ? | |||
| EBITDA margin, % | ? | -1 397% | -1 486% | -2 009% | -1 501% | -1 140% | -5 829% | |
| Changes by years, y/y, % | -1 264pp | -1 361pp | -1 654pp | +451pp | +257pp | |||
| Changes by quarters, q/q, % | +555pp | -89pp | -523pp | +508pp | +361pp | |||
